182 related articles for article (PubMed ID: 33475222)
21. Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
Farngren J; Persson M; Ahrén B
Diabetes Care; 2016 Feb; 39(2):242-9. PubMed ID: 26537183
[TBL] [Abstract][Full Text] [Related]
22. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
Bolli GB; Owens DR
Diabetes Obes Metab; 2014 Jul; 16(7):588-601. PubMed ID: 24373190
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.
Horowitz M; Rayner CK; Jones KL
Adv Ther; 2013 Feb; 30(2):81-101. PubMed ID: 23423907
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis.
Sheu WH; Brunell SC; Blase E
Diabetes Res Clin Pract; 2016 Apr; 114():160-72. PubMed ID: 26827116
[TBL] [Abstract][Full Text] [Related]
25. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
[TBL] [Abstract][Full Text] [Related]
26. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
Raccah D; Gourdy P; Sagnard L; Ceriello A
Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.
Gómez-Huelgas R; Azriel S; Puig-Domingo M; Vidal J; de Pablos-Velasco P
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):230-40. PubMed ID: 25066229
[TBL] [Abstract][Full Text] [Related]
28. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
Trujillo JM; Goldman J
Pharmacotherapy; 2017 Aug; 37(8):927-943. PubMed ID: 28556176
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
Ahrén B; Leguizamo Dimas A; Miossec P; Saubadu S; Aronson R
Diabetes Care; 2013 Sep; 36(9):2543-50. PubMed ID: 23536584
[TBL] [Abstract][Full Text] [Related]
30. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Sjöstrand M; Iqbal N; Lu J; Hirshberg B
Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
[TBL] [Abstract][Full Text] [Related]
31. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
[TBL] [Abstract][Full Text] [Related]
32. Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.
Yao J; Zhang M; Zhang X; Zhang J
Diabetes Ther; 2023 Apr; 14(4):653-669. PubMed ID: 36809495
[TBL] [Abstract][Full Text] [Related]
33. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
[TBL] [Abstract][Full Text] [Related]
34. Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering.
Fleischmann H; Göke R; Bramlage P
Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S91-S97. PubMed ID: 27986406
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.
Yabe D; Ambos A; Cariou B; Duvnjak L; Evans M; González-Gálvez G; Lin J; Nikonova EV; de Pablos-Velasco P; Yale JF; Ahrén B
J Diabetes Complications; 2016; 30(7):1385-92. PubMed ID: 27267268
[TBL] [Abstract][Full Text] [Related]
36. Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.
McCarty D; Coleman M; Boland CL
Ann Pharmacother; 2017 May; 51(5):401-409. PubMed ID: 28133970
[TBL] [Abstract][Full Text] [Related]
37. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
Giorgino F; Caruso I; Napoli R
Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
39. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.
Ratner RE; Rosenstock J; Boka G;
Diabet Med; 2010 Sep; 27(9):1024-32. PubMed ID: 20722676
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
